论文部分内容阅读
目的:探讨联合检测血清CA125、抑制素A(INH-A)和IL-8水平对卵巢癌早期诊断的价值.方法应用化学发光法和酶免法对41例卵巢癌、31例卵巢良性疾病和35例正常人进行了血清CA125、INH-A和IL-8水平检测.结果:卵巢癌组血清CA125、INH-A和IL-8水平非常显著地高于卵巢良性疾病组和正常人组(P<0.01).三项标志物的阳性率分别为73.2%、65.8%、61%.三项联合检测的阳性率为85.4%.卵巢癌组血清CA125水平与INH-A、IL-8水平呈显著正相关(r=0.427、0.484、p<0.01).结论:联合检测血清CA125、INH-A和IL-8有助于早期诊断卵巢癌以及病情监测.“,”Objective:To explore the early diagnostic Values of Combined detection of Serum CA125、INH-A and IL-8 Levels in patients with Ovarian cancer.Methods:Serum CA125、INH-A(with CLIA).Serum IL-8(with RIA)levels were measured in 41 patients with ovarian cancer.,31 patients with benign ovarian diseases and 35 controls.Results:The Serum CA125、INH-8 and IL-8 Levels and positive rat in patients with ovarian cancer were significantly higher than those of in patients with benign ovarian tumor and controls(p<0.05).The positive rates of CA125、INH-A、IL-8 in patients with ovarian cancer were 73.2%、65.8%、61.0%respectively.The positive rate of three markers combined detection was 85.4%.Sercum CA125 Levels were positively correlated with Serum INH-A、IL-8 Levels(r=0.4786、0.5125、p<0.01).Conclusions:Combined of detection of Serum CA125、INH-A and IL-8 levels maybe helpful for early diagnosis of ovarian cancer and diseases monitoring.